ResMed (NYSE:RMD – Get Free Report) released its earnings results on Thursday. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.17, Briefing.com reports. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter last year, the business earned $1.64 EPS. The business’s revenue was up 11.1% on a year-over-year basis.
ResMed Stock Up 7.1 %
Shares of NYSE RMD traded up $17.02 during mid-day trading on Friday, reaching $256.07. 3,516,490 shares of the company were exchanged, compared to its average volume of 1,046,026. The firm has a 50-day moving average of $240.22 and a 200 day moving average of $217.35. ResMed has a 1 year low of $132.24 and a 1 year high of $260.49. The company has a quick ratio of 1.69, a current ratio of 2.59 and a debt-to-equity ratio of 0.14. The stock has a market cap of $37.58 billion, a price-to-earnings ratio of 36.95, a P/E/G ratio of 1.94 and a beta of 0.69.
ResMed Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be paid a dividend of $0.53 per share. The ex-dividend date is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.83%. ResMed’s dividend payout ratio is presently 30.59%.
Insider Buying and Selling at ResMed
Wall Street Analysts Forecast Growth
Several analysts have issued reports on RMD shares. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Bank of America increased their price target on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. KeyCorp boosted their price objective on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday. Wolfe Research reiterated an “underperform” rating and issued a $180.00 target price on shares of ResMed in a research note on Wednesday, September 18th. Finally, Robert W. Baird boosted their target price on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $220.55.
Get Our Latest Stock Report on ResMed
About ResMed
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
See Also
- Five stocks we like better than ResMed
- Stock Market Upgrades: What Are They?
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Growth Stocks and Investing in Them
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.